Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

The Heart Failure Frequent Flyer Programme changes the trajectories of patients with chronic heart failure

24 Aug 2020
Chronic heart failure (CHF) is a significant public health concern, affecting at least 26 million individuals worldwide.1 In this case study, Professor Dr Chee Kok Han and Dr Nur Asyikin share their clinical experience running the Heart Failure Frequent Flyer Programme – an initiative between HTAR and UMMC. The Programme enrols CHF patients who had been hospitalised for HF at least twice over the past 12 months and diagnosed with New York Heart Association (NYHA) class II–IV.2

CHF is a frequent cause of hospitalisation at HTAR – a total of 1,140 patients were admitted for CHF between April 2017 and April 2018, with a mean length of stay of 8.2 days. In addition to causing high mortality, hospitalisation for HF (HHF) also places a significant financial burden on patients and the healthcare system. Notably, frequent hospitalisation strongly predicts mortality among patients with CHF – approximately 93% of CHF patients treated at HTAR have recent histories of recurrent admission to the hospital for worsening HF.

The Heart Failure Frequent Flyer Programme was set up with the principal goal of reducing hospitalisation in patients with CHF to improve functional status, quality of life (QoL) and cost of care.The Programme is conducted via a holistic and multidisciplinary approach, incorporating a dedicated HF team (consisting of clinical specialists, clinical pharmacists, HF nurses, dietitian and cardiac rehabilitation team), pharmacist-led patient counselling sessions, as well as nurse-led telemonitoring and SOS walk-in services.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.